Nyxoah SA
XBRU:NYXH

Watchlist Manager
Nyxoah SA Logo
Nyxoah SA
XBRU:NYXH
Watchlist
Price: 8.88 EUR -0.22%
Market Cap: 305.2m EUR
Have any thoughts about
Nyxoah SA?
Write Note

Intrinsic Value

NYXH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NYXH stock under the Base Case scenario is 3.44 EUR. Compared to the current market price of 8.88 EUR, Nyxoah SA is Overvalued by 61%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NYXH Intrinsic Value
3.44 EUR
Overvaluation 61%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Nyxoah SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NYXH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NYXH?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Nyxoah SA

Provide an overview of the primary business activities
of Nyxoah SA.

What unique competitive advantages
does Nyxoah SA hold over its rivals?

What risks and challenges
does Nyxoah SA face in the near future?

Has there been any significant insider trading activity
in Nyxoah SA recently?

Summarize the latest earnings call
of Nyxoah SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Nyxoah SA.

Provide P/S
for Nyxoah SA.

Provide P/E
for Nyxoah SA.

Provide P/OCF
for Nyxoah SA.

Provide P/FCFE
for Nyxoah SA.

Provide P/B
for Nyxoah SA.

Provide EV/S
for Nyxoah SA.

Provide EV/GP
for Nyxoah SA.

Provide EV/EBITDA
for Nyxoah SA.

Provide EV/EBIT
for Nyxoah SA.

Provide EV/OCF
for Nyxoah SA.

Provide EV/FCFF
for Nyxoah SA.

Provide EV/IC
for Nyxoah SA.

Show me price targets
for Nyxoah SA made by professional analysts.

What are the Revenue projections
for Nyxoah SA?

How accurate were the past Revenue estimates
for Nyxoah SA?

What are the Net Income projections
for Nyxoah SA?

How accurate were the past Net Income estimates
for Nyxoah SA?

What are the EPS projections
for Nyxoah SA?

How accurate were the past EPS estimates
for Nyxoah SA?

What are the EBIT projections
for Nyxoah SA?

How accurate were the past EBIT estimates
for Nyxoah SA?

Compare the revenue forecasts
for Nyxoah SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Nyxoah SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Nyxoah SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Nyxoah SA compared to its peers.

Compare the P/E ratios
of Nyxoah SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Nyxoah SA with its peers.

Analyze the financial leverage
of Nyxoah SA compared to its main competitors.

Show all profitability ratios
for Nyxoah SA.

Provide ROE
for Nyxoah SA.

Provide ROA
for Nyxoah SA.

Provide ROIC
for Nyxoah SA.

Provide ROCE
for Nyxoah SA.

Provide Gross Margin
for Nyxoah SA.

Provide Operating Margin
for Nyxoah SA.

Provide Net Margin
for Nyxoah SA.

Provide FCF Margin
for Nyxoah SA.

Show all solvency ratios
for Nyxoah SA.

Provide D/E Ratio
for Nyxoah SA.

Provide D/A Ratio
for Nyxoah SA.

Provide Interest Coverage Ratio
for Nyxoah SA.

Provide Altman Z-Score Ratio
for Nyxoah SA.

Provide Quick Ratio
for Nyxoah SA.

Provide Current Ratio
for Nyxoah SA.

Provide Cash Ratio
for Nyxoah SA.

What is the historical Revenue growth
over the last 5 years for Nyxoah SA?

What is the historical Net Income growth
over the last 5 years for Nyxoah SA?

What is the current Free Cash Flow
of Nyxoah SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Nyxoah SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Nyxoah SA

Current Assets 89.7m
Cash & Short-Term Investments 77.8m
Receivables 5.5m
Other Current Assets 6.4m
Non-Current Assets 58.6m
PP&E 7.8m
Intangibles 49.3m
Other Non-Current Assets 1.5m
Current Liabilities 16.4m
Accounts Payable 4.1m
Accrued Liabilities 3.2m
Other Current Liabilities 9.1m
Non-Current Liabilities 11.7m
Long-Term Debt 11.3m
Other Non-Current Liabilities 384k
Efficiency

Earnings Waterfall
Nyxoah SA

Revenue
4.8m EUR
Cost of Revenue
-1.8m EUR
Gross Profit
3m EUR
Operating Expenses
-50.3m EUR
Operating Income
-47.3m EUR
Other Expenses
3.8m EUR
Net Income
-43.5m EUR

Free Cash Flow Analysis
Nyxoah SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Nyxoah, in a pivotal year, focuses on U.S. market entry after DREAM study success and FDA submission. With €85 million raised, extending their cash runway to mid-2026, they are building their U.S. team. First half 2024 saw a 29% rise in European sales to €2 million. They plan FDA approval by late 2024, aiming for profitability at $250 million in U.S. sales. Loic Moreau highlighted a revenue decrease to €780,000 in Q2, with an operating loss increase to €13.3 million, driven by expansion costs. Their innovative Genio system promises less invasiveness and strong patient outcomes, boosting their U.S. market confidence.

What is Earnings Call?
Fundamental Scores

NYXH Profitability Score
Profitability Due Diligence

Nyxoah SA's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
38/100
Profitability
Score

Nyxoah SA's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

NYXH Solvency Score
Solvency Due Diligence

Nyxoah SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
63/100
Solvency
Score

Nyxoah SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NYXH Price Targets Summary
Nyxoah SA

Wall Street analysts forecast NYXH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYXH is 14.54 EUR with a low forecast of 10.1 EUR and a high forecast of 18.69 EUR.

Lowest
Price Target
10.1 EUR
14% Upside
Average
Price Target
14.54 EUR
64% Upside
Highest
Price Target
18.69 EUR
110% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NYXH?

Click here to dive deeper.

Dividends

Nyxoah SA
does not pay dividends
Shareholder Yield

Current shareholder yield for NYXH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NYXH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Nyxoah SA Logo
Nyxoah SA

Country

Belgium

Industry

Health Care

Market Cap

305.9m EUR

Dividend Yield

0%

Description

Nyxoah SA engages in the research and development, manufacture and sale of medical devices. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 72 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Contact

BRABANT-WALLON
Mont-Saint-Guibert
Rue Edouard Belin 12
+3226121755.0
www.nyxoah.com

IPO

2020-09-18

Employees

72

Officers

Co-Founder & Chairman
Mr. Robert Taub MBA
CEO & Executive Director
Mr. Olivier Taelman
Chief Financial Officer
Mr. Loic Moreau
Chief Technology Officer
Mr. Bruno Onkelinx
Corporate Communication & Investor Relations Manager
Mikaela Kirkwood
General Counsel
Ms. An Moonen
Show More
Global Human Resource Director
Ms. Inge Vanwittenbergh
Chief of Staff
Mr. Remi Renard
Chief Clinical Officer
Mr. Jeyakumar Subbaroyan
Chief Regulatory & Quality Officer
Mr. Francis S. Kim
Show Less

See Also

Discover More
What is the Intrinsic Value of one NYXH stock?

The intrinsic value of one NYXH stock under the Base Case scenario is 3.44 EUR.

Is NYXH stock undervalued or overvalued?

Compared to the current market price of 8.88 EUR, Nyxoah SA is Overvalued by 61%.

Back to Top